|
Melarsoprol (INN) is a prodrug used in the treatment of East African (rhodesiense) human African trypanosomiasis. It is produced by Sanofi-Aventis and is on the World Health Organization's List of Essential Medicines. Freidheim demonstrated in 1949 the effects of melarsoprol against late-state trypanosomiasis. Melarsoprol is the dimercaptopropanol derivative of melarsen oxide (Mel Ox), whose structure is shown below: The main drug prescribed is Mel B, however, an alarming number of side effects occur from treatment. The active metabolite of Mel B is Mel Ox, which is taken up by the TbAT1 adenosine transporter in ''T. brucei brucei''. Due to side effects similar to arsenic poisoning, other pharmacological agents have become first-line treatments for stage one of the disease and for certain trypanosomes. ==Treatment== All people with confirmed trypanosome-caused disease must be treated. Treatment differs based on whether disease levels are considered stage 1 or stage 2 and based on which specific trypanosome has infected a patient. Below are treatment options (all adapted from ). Melasarprol is used in the treatment of the second stage of the disease, and is the only treatment available for late-stage ''T. b. rhodesiense'' treatment. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Melarsoprol」の詳細全文を読む スポンサード リンク
|